Anemia In Chronic Kidney Disease - Pipeline Insight, 2020
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Anemia in Chronic Kidney Disease – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anemia in Chronic Kidney Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Anemia in Chronic Kidney Disease: Overview
Anemia is a frequent complication of Chronic Kidney Disease. The major cause of anemia in patients with CKD is the decreased ability of kidneys to produce erythropoietin (EPO). Decreased erythrocyte counts leads to insufficient oxygen supply in organs and decreases mobility and activities in daily life, which ultimately leads to a poor quality of life. Anemia might begin in early stages of CKD and usually gets worse as CKD gets progress. Anemia in CKD is typically normocytic, normochromic, and hypoproliferative.
Symptoms
The symptoms of Anemia in Chronic Kidney Disease include:
A diagnosis of Anemia in Chronic Kidney Disease is based upon a thorough clinical evaluation and a detailed patient history. The laboratory tests including RBC indices, Peripheral blood smear, Reticulocyte count Test are vital in the evaluation of anemia of chronic illness or chronic kidney disease. Diagnosis of anemia of renal disease is based on demonstration of renal insufficiency, normocytic anemia, and peripheral reticulocytopenia.
Treatment
Pateints with anemia with chronic kidney disease can be treated on an outpatient basis. Depending on the cause, treatments options include Iron Supplements, Erythropoiesis-stimulating agents (ESAs), Red Blood Cell Transfusions, and Vitamin B12 and Folic Acid Supplements.
Anemia in Chronic Kidney Disease Emerging Drugs Chapters
This segment of the Anemia in Chronic Kidney Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anemia in Chronic Kidney Disease Emerging Drugs
Further product details are provided in the report
Anemia in Chronic Kidney Disease: Therapeutic Assessment
This segment of the report provides insights about the different Anemia in Chronic Kidney Disease drugs segregated based on following parameters that define the scope of the report, such as:
Anemia in Chronic Kidney Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anemia in Chronic Kidney Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anemia in Chronic Kidney Disease drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Anemia in Chronic Kidney Disease – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anemia in Chronic Kidney Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Anemia in Chronic Kidney Disease: Overview
Anemia is a frequent complication of Chronic Kidney Disease. The major cause of anemia in patients with CKD is the decreased ability of kidneys to produce erythropoietin (EPO). Decreased erythrocyte counts leads to insufficient oxygen supply in organs and decreases mobility and activities in daily life, which ultimately leads to a poor quality of life. Anemia might begin in early stages of CKD and usually gets worse as CKD gets progress. Anemia in CKD is typically normocytic, normochromic, and hypoproliferative.
Symptoms
The symptoms of Anemia in Chronic Kidney Disease include:
- weakness
- fatigue, or feeling tired
- headaches
- problems with concentration
- paleness
- dizziness
- difficulty breathing or shortness of breath
- chest pain
A diagnosis of Anemia in Chronic Kidney Disease is based upon a thorough clinical evaluation and a detailed patient history. The laboratory tests including RBC indices, Peripheral blood smear, Reticulocyte count Test are vital in the evaluation of anemia of chronic illness or chronic kidney disease. Diagnosis of anemia of renal disease is based on demonstration of renal insufficiency, normocytic anemia, and peripheral reticulocytopenia.
Treatment
Pateints with anemia with chronic kidney disease can be treated on an outpatient basis. Depending on the cause, treatments options include Iron Supplements, Erythropoiesis-stimulating agents (ESAs), Red Blood Cell Transfusions, and Vitamin B12 and Folic Acid Supplements.
Anemia in Chronic Kidney Disease Emerging Drugs Chapters
This segment of the Anemia in Chronic Kidney Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anemia in Chronic Kidney Disease Emerging Drugs
- BCD-066: Biocad
- SSS17: Shenyang Sunshine Pharmaceutical
Further product details are provided in the report
Anemia in Chronic Kidney Disease: Therapeutic Assessment
This segment of the report provides insights about the different Anemia in Chronic Kidney Disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Anemia in Chronic Kidney Disease
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Anemia in Chronic Kidney Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anemia in Chronic Kidney Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anemia in Chronic Kidney Disease drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Anemia in Chronic Kidney Disease R&D. The therapies under development are focused on novel approaches to treat/improve Anemia in Chronic Kidney Disease.
- Anemia in Chronic Kidney Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Anemia in Chronic Kidney Disease drugs?
- How many Anemia in Chronic Kidney Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Anemia in Chronic Kidney Disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anemia in Chronic Kidney Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Anemia in Chronic Kidney Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
- Pieris Pharmaceuticals
- Jiangsu HengRui Medicine
- Shenyang Sunshine Pharmaceutical
- Biocad
- Xenetic Biosciences
- Chiasma
- Liminal BioSciences
- Acceleron Pharma
- Celgene Corporation
- PRS-080
- DDO-3055
- SSS17
- BCD-131
- BCD-066
- Erythropoietin polysialic
- CHIP 2
- PBI 1402
- Sotatercept
Introduction
Executive Summary
Anemia in Chronic Kidney Disease: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Anemia in Chronic Kidney Disease – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Anemia in Chronic Kidney Disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Anemia in Chronic Kidney Disease Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Darbepoetin alfa biosimilar: Biocad
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
BCD-131: Biocad
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
DDO-3055: Jiangsu HengRui Medicine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Anemia in Chronic Kidney Disease Key Companies
Anemia in Chronic Kidney Disease Key Products
Anemia in Chronic Kidney Disease- Unmet Needs
Anemia in Chronic Kidney Disease- Market Drivers and Barriers
Anemia in Chronic Kidney Disease- Future Perspectives and Conclusion
Anemia in Chronic Kidney Disease Analyst Views
Anemia in Chronic Kidney Disease Key Companies
Appendix
Executive Summary
Anemia in Chronic Kidney Disease: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Anemia in Chronic Kidney Disease – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Anemia in Chronic Kidney Disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Anemia in Chronic Kidney Disease Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Darbepoetin alfa biosimilar: Biocad
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
BCD-131: Biocad
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
DDO-3055: Jiangsu HengRui Medicine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Anemia in Chronic Kidney Disease Key Companies
Anemia in Chronic Kidney Disease Key Products
Anemia in Chronic Kidney Disease- Unmet Needs
Anemia in Chronic Kidney Disease- Market Drivers and Barriers
Anemia in Chronic Kidney Disease- Future Perspectives and Conclusion
Anemia in Chronic Kidney Disease Analyst Views
Anemia in Chronic Kidney Disease Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Anemia in Chronic Kidney Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Anemia in Chronic Kidney Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Anemia in Chronic Kidney Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Anemia in Chronic Kidney Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
